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ABSTRACT
Multicellular three-dimensional (3D) spheroids represent an experimental model 
that is intermediate in its complexity between monolayer cultures and patients’ tumor. 
In the present study, we characterize multicellular spheroids from papillary (PTC) and 
follicular (FTC) thyroid cancers and from the corresponding normal tissues. We show 
that these 3D structures well recapitulate the features of the original tissues, in either 
the differentiated and “stem-like” components. As a second step, we were aimed to 
test the effects of a small multikinase inhibitor, SP600125 (SP), previously shown to 
efficiently induce cell death in undifferentiated thyroid cancer monolayer cultures. We 
demonstrate the potent effect of SP on cell growth and survival in our 3D multicellular 
cultures. SP exerts its main effects through direct and highly significant inhibition 
of the ROCK pathway, known to be involved in the regulation of cell migration and 
β-catenin turnover. Consistently, SP treatment resulted in a significant decrease in 
β-catenin levels with respect to basal conditions in tumor but not in normal spheroids, 
indicating that the effect is promisingly selective on tumor cells.
In conclusion, we provide the morphological and molecular characterization of 
thyroid normal and tumor spheroids. In this 3D model we tested in vitro the effects 
of the multikinase inhibitor SP and further characterized its mechanism of action in 
both normal and tumor spheroids, thus making it an ideal candidate for developing 
new drugs against thyroid cancer.
INTRODUCTION
Multicellular three-dimensional spheroids represent 
an experimental model that is intermediate in its complexity 
between monolayer cultures and patients’ tumor, and are thus 
successfully used in cancer research [1, 2]. Differently from 
two-dimensional monolayer cultures, the primary spheroids 
retain a three-dimensional (3D) structure, forming intercellular 
contacts, and usually displaying radial gradients of oxygen, 
glucose, and other nutrients with low values in the center, 
thus mimicking the natural environment of solid tumors [1]. 
Although several kinds of cancer cells have already been 
cultured as multicellular spheroids and used for investigation of 
tumor cell growth and response to various kinds of treatments 
[2, 3], most in vitro studies on human thyroid carcinoma cells 
have been so far conducted on monolayer cultures [4–6].
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In the last decade, novel therapeutic options have 
been released for radioiodine refractory thyroid cancer 
(TC) based on the administration of kinase inhibitors 
mainly directed against RAS/RAF/ERK and AKT/mTOR 
pathways [7]. We recently demonstrated, in normal and 
cancer thyroid derived cell lines, cultured in monolayer, 
that the kinase inhibitor SP600125 (SP) is highly effective 
in blocking cell growth and migration and in the induction 
of mitotic catastrophe through direct inhibition of ROCK, 
a kinase involved in the regulation of cell migration, 
microtubule dynamics and β-catenin turnover [8]. This 
mechanism of action may be particularly important in 
anticancer therapy considering that Rho/ROCK pathway 
is hyperactivated in different human neoplasia and its 
activity correlates with metastatic disease [9–11]. SP 
was found to be particularly effective against poorly 
differentiated cancer cells and, at a lesser extent, on 
papillary thyroid cancer derived cells [8].
It is well known that the in vivo response to 
antineoplastic treatments is often short lasting due to 
selection of resistant clones apparently originating from 
the cancer stem cells (CSCs) [12, 13]. Cells with stem-
like properties represent a very small percentage of the 
thyroid cell population (<1%), but they have been detected 
in normal thyroid, in multinodular goiters and in thyroid 
cancers, though limited and controversial data exist on 
their characterization [14–16].
Hence, in the present study we used appropriate 
conditions [17] in order to maintain and possibly increase 
the amount of cells with stem-like properties among the 
heterogeneous population of the multicellular thyroid 
spheroids obtained from 17 papillary and 4 follicular 
tumor tissues, and from the matched normal tissues, and 
we aimed to get more insights into the effects of SP by 
testing it in our multicellular spheroid model which 
recreates in culture the typical 3D architecture of the 
tissue.
RESULTS
Thyroid spheroids derived from thyroid 
cancer and contralateral normal tissues are 
morphologically different
After 7 days of culture in low attachment condition 
and serum-free medium, spheroids were obtained from 
all 21 thyroid cancers and matched normal specimens. 
In all cases, the thyroid spheroids were morphologically 
different according to the tissue of origin. In particular, 
spheroids obtained from 17 papillary thyroid cancers 
(PTCs) showed a variable morphology (from irregular 
to regular shape and border) and size (indicating 
heterogeneous proliferation rates), whereas spheroids 
from 4 follicular thyroid cancers (FTCs) and contralateral 
normal thyroid tissues had a more regular shape and 
well-defined borders. The number of spheroids/well 
was significantly higher for those derived from PTC 
tissues with respect to those derived from FTC or normal 
tissues (239.2 ± 29.88 vs 35.71 ± 4.52 and 78.83 ± 25.41, 
respectively; P<0.0001 and P=0.002, respectively). 
Moreover, the size of FTC spheroids was significantly 
larger than that of PTC and normal spheroids (170.7 ± 
6.256 vs 89.36 ± 3.877 and 111.2 ± 9.377, respectively; 
P<0.0001). Finally, PTC spheroids tended to have a more 
solid appearance with respect to the hollow morphology 
observed in thyroid spheroids from FTC and normal 
samples (Figure 1).
Thyroid tissues and the derived spheroids have 
the same genetic pattern
Among the 17 PTCs analyzed, 9 harbored the 
BRAFV600E mutation and 2 a -124 C > T (C228T) TERT 
mutation, while N-RAS mutations were found in 2 FTCs 
(Q61R and Q61K) and the C228T TERT mutation in 2 
FTCs. In 8 tumors no mutations were identified, though 
it should be highlight that Sanger sequencing harbors a 
relatively low sensitivity and there is a possibility that 
some mutations could have been missed if present in a 
small percentage of tumor cells. Interestingly, the genetic 
pattern of the tumor tissues and that of the deriving 
spheroids was always concordant. In order to test possible 
variations in the genetic pattern during culture, 3 cases 
were studied at different time points (7, 14 and 21 days), 
and no variation in the genetic pattern was observed 
(Table 1). Moreover, no morphological differences were 
noted among thyroid tumor spheroids harboring different 
genetic alterations.
The expression of thyroid differentiation cell 
markers is maintained in spheroids derived from 
PTCs, FTCs and normal thyroid tissues
The expression of thyroid differentiation markers, 
TG (thyroglobulin) and TTF1, was maintained in 
spheroids and was variable, mostly sparse in spheroids 
from normal tissues or preferentially located in the 
peripheral area of tumor spheroids (Figure 2).
Endothelial and hematopoietic markers are 
expressed in PTCs, FTCs and normal thyroid 
tissues and in the derived spheroids
The leucocyte common antigen CD45 was never 
expressed in PTC or normal thyroid spheroids here 
analysed, while its expression was detected in some 
cells within FTC spheroids. CD45-positive cells 
were more present in FTC than in PTC or in normal 
spheroids. On the other hand, a strong staining for 
the hematopoietic/endothelial marker CD34 and the 
endothelial antigen CD31 was found in both PTC and 
normal spheroids. Interestingly, these positive cells 
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were found to be located in the spheroids’ core, showing 
a flattened nucleus and a morphology resembling 
endothelial cells. The mean values of stained cells 
obtained in multiple replicates of PTC, FTC and normal 
spheroids are reported in Figure 3.
Embryonic stem cell markers are expressed in 
PTCs, FTCs and in the derived spheroids
Among the nuclear embryonic stem cell markers 
examined in PTC and FTC sections, NANOG resulted 
Figure 1: Thyroid spheroids derived from thyroid cancer and contralateral normal tissues are morphologically and 
numerically different. Spheroids display a different morphology depending on the tissue from which they have been obtained. Spheroids 
obtained from fresh papillary thyroid cancer after 7 days of culture in serum-free and anchorage-independent conditions may display an 
irregular A. or regular B. shape. On the other hand, those obtained from follicular thyroid cancer C. or normal thyroid tissue D. always 
show, under the same conditions, a regular and more spherical shape. Spheroids from follicular tumors and from normal thyroid tissues 
generally display a hollow morphology, while spheroids from papillary tumors show a more solid pattern (Original magnification, 50X). 
Moreover, spheroids derived from follicular thyroid cancers (FTC) are usually larger than those from papillary tumors (PTC) and normal 
thyroid tissues E. while the number of spheroids/well is significantly higher for those derived from PTC with respect to those derived 
from FTC or normal tissues F. Values are given as mean ± SEM from different preparations from independent patients. Spheroids size was 
calculated using AxioVision software rel. 4.8, while spheroids/well were counted using a Leica DMD108 digital microimaging instrument, 
considering three fields for each preparation.
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to be expressed in few cells, whereas a diffuse 
expression was observed in the corresponding spheroids 
(Figure 4, panel A). At variance, POU5F1/OCT4 was 
expressed in the majority (50-80%) of either PTCs or 
FTCs tissues, and its expression was maintained also 
in the corresponding spheroids (Figure 4, panel A). 
A weaker expression of these markers was found in 
both the normal tissues and in the derived spheroids. 
Interestingly, the immunohistochemistry analysis for 
the stem cell marker POU5F1/OCT4 and the thyroid 
differentiation marker TG on consecutive paraffin-
embedded tumor spheroids sections allowed us to 
demonstrate that POU5F1/OCT4 cells mostly located 
in the centre while TG cells at the periphery of the 
spheroids (Figure 4, Panel B).
SP inhibits cell proliferation in multicellular 
tumor spheroids
SP anti-proliferative effects were assessed in vitro 
on thyroid multicellular spheroids derived from tumors 
and their corresponding normal thyroid tissues, carrying 
different genetic alterations (patients #28-34). SP was 
highly effective against both PTC and FTC spheroids, 
whereas no effect was observed in non-treated or in 
DMSO treated tumor spheroids. In particular, tumor 
spheroids surviving 96 hours of SP treatment appeared 
as smaller, inhomogeneous and irregular aggregates. This 
was consistent with the significant reduction in the protein 
content with respect to untreated spheroids (P<0.0001, 
Figure 5). Importantly, no effects were noted in normal 
Table 1: Clinical and histological characteristics of the tumors included in the study. The genetic characterization is 
also reported. In all cases the genetic pattern of the tissues and of the matched spheroids areconcordant
# gender age histology pTNM TERT BRAF N-, H-, K-RAS RET/
PTC
TRK/T
1 F 39 CPTC T1amNX WT WT WT WT nd
2 F 42 CPTC T1bN0 WT V600E WT WT WT
3 F 41 FTC T2Nx C228T nd WT nd nd
5 F 26 CPTC T3mN1a WT V600E WT WT nd
7 F 46 CPTC T1mN0 WT WT WT WT WT
8 M 32 FVPTC T3mN1b WT WT WT WT nd
9* M 65 CPTC T3N1b WT V600E WT WT WT
10 M 52 CPTC T3N1a WT V600E WT WT WT
11* F 81 FTC T3aN0 WT nd WT nd nd
12 F 44 CPTC T3mN0 C228T WT WT WT WT
14 M 28 CPTC T3N1 WT WT WT WT WT
15 F 39 FTC + insular T3mNx WT nd Q61R (N) nd nd
19 F 36 CPTC T3N1a WT V600E WT WT nd
20* F 65 FVPTC T2mN0 WT V600E WT WT WT
28 F 69 CPTC T3mN1 C228T V600E WT WT WT
29 F 28 CPTC T1aN1b WT WT WT WT WT
30 F 35 CPTC T3N1a WT WT nd WT nd
31 F 39 CPTC T2N1a WT V600E WT WT WT
32 M 35 CPTC T2N1a WT WT WT WT WT
33 F 88 CPTC T3pN0 WT V600E WT WT WT
34 M 67 FTC T4bNX C228T nd Q61K (N) nd nd
Legend: CPTC: classical variant papillary thyroid cancer; FVPTC: follicular variant papillary thyroid cancer; FTC: 
follicular thyroid cancer; WT: wild-type; nd: not done. In italics cases submitted to SP treatment. * genetic pattern 
confirmed in spheroids at 7, 14 and 21 days of culture.
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Figure 2: The expression of thyroid differentiation cell markers is maintained in spheroids derived from PTCs, FTCs 
and normal thyroid tissues. The expression of the differentiation markers thyroglobulin (TG) and TTF1 is maintained in both papillary 
(PTC), follicular (FTC) and normal spheroids (cytoplasm and nucleus, respectively). The expression is variable, mostly sparse in spheroids 
from normal tissues or preferentially located in the peripheral area of tumor spheroids.
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Figure 3: Endothelial and hematopoietic markers are expressed in PTCs, FTCs and normal thyroid tissues and in the 
derived spheroids. A strong staining for the hematopoietic/endothelial marker CD34 and the endothelial antigen CD31 is observed in 
both papillary thyroid cancer (PTC) and normal spheroids. Interestingly, these two markers localize in the core of the spheroid. A mild or 
absent expression of both antigens is observed in follicular thyroid cancer (FTC) spheroids. On the contrary, the staining for the leucocyte 
common antigen CD45 is negative in both PTC and normal thyroid spheroids, and positive in some spheroids from FTC tissues. For CD31, 
CD34 and CD45, positive cells were scored out of the total cell number within at least 5 spheres for each sample (PTC, FTC and normal 
spheroids) and expressed as a percentage. Bars represent mean percentages ± SEM. Only significant differences are reported.
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Figure 4: Embryonic stem cell markers are expressed in PTCs, FTCs and in the derived spheroids. Panel A: In PTC and 
FTC tissues NANOG is expressed in few cells, whereas a diffuse expression is observed in the corresponding spheroids. POU5F1/OCT4 
is expressed in the majority (50-80%) of either PTCs or FTCs tissues, and its expression is maintained also in the corresponding spheroids. 
In normal tissues the expression of both markers is negative, while it is weak and diffuse in the corresponding normal thyroid spheroids. 
Panel B: The analysis for the stem cell marker POU5F1/OCT4 and the thyroid differentiation marker thyroglobulin (TG) on consecutive 
paraffin-embedded tumor spheroids sections shows that POU5F1/OCT4 cells mostly locate in the centre and TG cells at the periphery of 
the spheroids.
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spheroids. It is worth to note that SP anti-proliferative 
effects were not different among PTC and FTC cases, 
and among mutated or non-mutated spheroids (data not 
shown), though the sample analyzed is too limited to draw 
definite conclusions.
SP exerts its main effects through direct 
inhibition of ROCK pathway
The tumor spheroids had a significantly higher 
ROCK activity than normal spheroids (P=0.0004, Figure 
6 panel A). SP treatment was found to significantly reduce 
the ROCK activity in tumors spheroids and, at a lesser 
extent, in normal spheroids (P<0.0001 and P=0.007, 
Figure 6 panel A). As a second step, we examined 
whether these results were concordant with changes in the 
downstream pathway, and in particular in the β-catenin 
levels. Consistent with ROCK activity data, tumor 
spheroids showed a significant decrease in the β-catenin 
expression after SP treatment, whereas no differences were 
observed between treated and untreated normal spheroids 
(Figure 6, panel B).
DISCUSSION
Drug attrition rates for cancer are much higher 
than in other therapeutic areas. Only 5% of agents that 
have anticancer activity in preclinical development 
demonstrates a sufficient efficacy in phase III testing and 
reaches the patients [18]. This is not only an unacceptable 
waste of money, but means the loss of opportunities for 
those patients participating in unsuccessful clinical trials. 
The high attrition rates are largely due to the inappropriate 
conditions used in the preclinical phases that are poorly 
representative of the biological characteristics of the 
original tumor [19]. In this context, multicellular spheroids 
are emerged as an experimental model intermediate in 
their complexity between monolayer cultures and patients’ 
tumor [1, 2]. Several methods have been developed to 
generate multicellular tumor spheroids, some of which 
are scaffold-based (e.g., matrix-on-top, matrix-embedded, 
matrix encapsulation, spinner flasks, micropatterned 
plates, liquid overlay) while others are scaffold-free 
methods (e.g., ultra-low attachment plates, hanging 
drop, rotary cell culture systems). In scaffold-based 
methods, extracellular membrane-based natural hydrogels 
(such as Matrigel or Agar) and synthetic or engineered 
hydrogels are commonly used. Among scaffold-free 
methods, promising NASA rotary cell culture systems 
(Random Positioning Machine and Rotating wall vessels), 
which simulate a near-weightlessness environment or 
microgravity are included [2, 20].
In the present study, a model of multicellular 
tumor and normal thyroid spheroids was established 
using nonadherent conditions (ultra-low attachment 
plates). We show that spheroids are morphologically and 
Figure 5: SP inhibits cell proliferation in multicellular tumor spheroids. In the upper panels normal and tumor spheroids are 
shown, either non-treated or DMSO treated (DMSO), or SP600125 (20 μM 96 hrs) treated (SP). The lower panel reports data on the cell 
proliferation in non-treated and treated normal and tumor spheroids. Tumor spheroids have a significant reduction in the number, the size 
and the total protein amount after SP treatment.
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Figure 6: SP acts through ROCK pathway inhibition. Panel A: Basal status of ROCK pathway and SP-induced modifications 
in normal and tumor spheroids. Quantification of ROCK activity at baseline and after incubation with 20 μM SP or equivalent amount 
of DMSO for 96 hours. Values are given as mean ± SEM. Panel B: Quantification of β-catenin expression and representative images of 
western blots showing total amount of β-catenin in non-treated spheroids, and after incubation of normal and tumor spheroids with 20 μM 
SP or equivalent amount of DMSO for 96 hours; GAPDH was used as loading control. Ponceau S staining on the same membranes is also 
reported, confirming the uniformity of protein total amount in each sample. No significant variation in sample quantification is detected 
when normalizing for GAPDH or Ponceau staining. Values are given as mean ± SEM.
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numerically different according to the tissue of origin 
and have a genetic pattern always concordant with that 
of the corresponding tissue. The TG and TTF1 thyroid 
differentiation markers are expressed both in tumor and 
normal spheroids. The expression is lower in tumor 
spheroids, and very weak in those derived from PTCs, 
compared to normal spheroids.
In thyroid tumor tissues, contrasting and extremely 
partial data on stem markers expression are available in 
the literature. Indeed, in differentiated and undifferentiated 
thyroid cancers, POU5F1/OCT4 was variably expressed 
in some cases [21, 22], but not in others [23, 24]. In the 
tissues here characterized, POU5F1/OCT4 is the stem cell 
marker with the highest expression, with a particularly 
strong staining in FTCs. The expression of this stem 
gene is absent in normal thyroid tissues contralateral to 
tumors, consistent with recently reported data [16]. The 
immunostaining of tumor spheroids confirms the findings 
at the tissue level, with a strong expression of POU5F1/
OCT4, particularly in FTC spheroids. Interestingly, 
by means of immunohistochemistry on consecutive 
slides, we show that the stem marker POU5F1/OCT4 is 
mainly expressed in the core of spheroids, whereas TG 
has a peripheral expression. This is consistent with the 
notion that stem-like cells preferentially reside in niches 
characterized by hypoxia and low nutrients, such as the 
core of the spheroids.
Interestingly, in the spheroids core we show the 
expression of the hematopoietic/endothelial marker CD34 
and the endothelial antigen CD31 in cells, displaying 
a flattened nucleus typical of endothelial cells and 
mimicking the formation of vascular structures. However, 
the expression of hematopoietic and endothelial markers 
was heterogeneous among the different tumors and the 
corresponding spheroids.
As a second step, we evaluated the performance 
of this spheroid model in the testing of new molecules 
of potential interest in anticancer treatment. Currently, 
several tyrosine kinase inhibitors (such as Sorafenib or 
Lenvatinib) are used in protocols or as approved drugs in 
the treatment of advanced radioiodine-refractory thyroid 
cancer [25]. Nevertheless, the actual improvement of 
overall survival is questioned, the side effects have a 
major impact on the quality of life, and the resistance to 
treatment ensues with time in virtually all treated patients, 
likely due to the development of compensatory pathways 
and to the persistence of cancer stem cells. Thus, there 
is still the need to generate new and more effective 
drugs. We recently demonstrated that a small compound, 
SP600125 (SP), is able to induce the inhibition of cancer 
cell migration and cell death through mitotic catastrophe 
[8]. The effect was shown in two-dimensional cell cultures 
of well-differentiated, poorly differentiated and anaplastic 
thyroid cancer, being the highest effects observed in 
poorly differentiated and anaplastic cell lines [8]. In this 
study, we report the potent effect of SP on cell survival 
in our 3D multicellular cultures of neoplastic thyroid 
spheroids derived from papillary and follicular thyroid 
cancers. In particular, tumor spheroids surviving 96 hours 
of SP treatment become smaller, inhomogeneous and 
irregular, with a significant reduction in the protein content 
with respect to untreated spheroids. Importantly, the effect 
is selective on tumor spheroids in comparison to normal 
thyroid spheroids.
In cancer tissues and monolayer cultures [8], we 
found an increased ROCK activity and SP was shown to 
exert its main effect through direct and highly significant 
inhibition of this kinase that is involved in the regulation 
of cell migration, microtubule dynamics and β-catenin 
turnover [26, 27]. Indeed, β-catenin can act as pro-
proliferative factor and is involved in cancer invasiveness 
and metastatization, and its activity was found to be 
increased in several undifferentiated cancers [28, 29]. 
Here we show that ROCK activity is significantly higher 
in neoplastic spheroids than in normal ones, and SP 
treatment induces a significant decrease of ROCK activity 
and β-catenin levels in cancer spheroids, while minor or 
no effects were recorded in spheroids from normal tissues. 
These data further support SP as a promising therapeutic 
compound for thyroid cancer.
ROCK inhibitors are currently used in clinical trials 
for glaucoma, Raynaud phenomenon or vasoconstriction-
related diseases, and erectile dysfunction, either 
as ophthalmic solutions or as preparations for oral 
administration (https://clinicaltrials.gov/; https://www.
clinicaltrialsregister.eu/). For either the treatment of these 
diseases or as anticancer drugs, ROCK inhibitors have 
been tested at concentrations ranging 10-100 μM for in 
vitro, and 1-200 mg/kg/day for in vivo studies [30, 31]. 
According to the data available so far, SP600125 appears 
to be as effective as currently tested ROCK inhibitors, or 
even more effective. Indeed, we confirmed its efficacy 
at 20 μM concentration in accord with previous data 
reporting that in cell cultures it acts at concentrations as 
low as 5-20 μM, and in mice it reduces p53-defective 
cancer cells growth at the daily dose of 2.5 mg/kg [32].
In conclusion, we report a morphological and 
molecular characterization of normal and tumor thyroid 
spheroids. The analysis of the corresponding tissues, 
allows to conclude that the spheroids well recapitulate 
the characteristics of the tissues of origin, either in the 
differentiated and “stem-like” components. Another 
significant advantage of the spheroid model is the 
possibility to test cells derived from the normal tissues. 
This 3D model allowed to test in vitro the effects of the 
kinase inhibitor SP, which was found to be highly effective 
on both PTC and FTC derived spheroids. The effect of SP 
appears to be selective on tumor spheroids and it involves 
the direct inhibition of the ROCK-β-catenin pathway. 
This mechanism of action may be particularly important 
in anticancer therapy considering that Rho/ROCK/ 
β-catenin pathway is hyperactivated in neoplasia, and its 
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activity correlates with metastatic disease [8–11]. Further 
studies will be devoted to test other novel molecules in 
this spheroid model in order to identify possible novel 
drugs selective for neoplastic cells, including those with 
“stem-like” features.
MATERIALS AND METHODS
Chemicals
Cell culture reagents, Restore Western Blot Stripping 
reagent, monoclonal anti-GAPDH antibody and HRP 
conjugated secondary antibodies were purchased from 
Thermo Fisher Scientific (Waltham, Massachusetts, USA). 
SP600125 (1,9-Pyrazoloanthrone), DMSO, Ponceau 
S, collagenase type I, monoclonal anti-β-Catenin and 
anti-α-Tubulin antibodies were purchased from Sigma-
Aldrich (Saint Louis, MO, USA). Fibroblast growth 
factor (bFGF) and epidermal growth factor (EGF) were 
purchased from PeproTech EC (London, UK). Monoclonal 
anti-POU5F1/OCT4 antibody was purchased from Santa 
Cruz Biotechnology Inc. (Dallas, TX, USA); polyclonal 
anti-NANOG antibody from ReproCELL Inc. (Yokohama, 
Kanagawa, Japan), monoclonal anti-TTF1, TG, CD31, 
CD34 and CD45 antibodies from Cell Marque (Rocklin, 
CA, USA), and monoclonal anti-Actin Ab-5 from BD 
Italia, (Milan, Italy). Protease inhibitors cocktail tablets 
were purchased from Roche (Basel, Switzerland).
Samples
A total of 17 papillary (PTC) and 4 follicular 
(FTC) tumor tissues, and the corresponding contralateral 
normal tissues were obtained from patients undergoing 
thyroidectomy for thyroid cancer (Table 1). All samples 
were obtained at the time of surgery in the Endocrine 
Surgery Unit, and immediately dissected by the pathologist 
under sterile conditions. In particular, the “core” of 
the tumor was carefully isolated to ensure the highest 
percentage of tumor cells and to avoid contamination 
with normal thyroid tissue. Fresh specimens were used 
for spheroids cultures and genetic analyses, while the 
corresponding paraffin embedded samples were used 
for immunohistochemistry analysis. All patients gave 
informed consent to the study, which was approved by the 
local Ethical Committee.
Thyroid spheroids cultures
Tumor and normal thyroid tissues were digested in 
DMEM/2 mg/ml collagenase type I (Sigma-Aldrich, Saint 
Louis, MO, USA) at 37°C for 2 h. Cells were seeded at 
5x105 cells and grown in serum-free medium: DMEM/F12 
1:1 medium (Gibco-Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) containing 20 ng/ml human basic 
fibroblast growth factor-bFGF (PeproTech EC, London, 
UK), 20 ng/ml human epidermal growth factor-EGF 
(PeproTech EC, London, UK), B27 (1:50 dilution, 
Gibco-Invitrogen, Carlsbad, CA, USA), antibiotics and 
Fungizone (Gibco-Thermo Fisher Scientific Waltham, 
Massachusetts, USA) in ultra-low attachment 6 well 
plates (Corning Incorporated Life Science, Tewksbury, 
MA, USA). The wells of the ultra-low attachment plates 
are coated with polystyrene, an inert substrate, which 
blocks cell attachment and induces cells in suspension to 
aggregate into visible spheroids. The cells were incubated 
in a 37°C, 5% CO2 incubator and floating primary 
aggregates of cells with spheroid-like structure appeared 
after 7 days, and fresh medium was added to wells weekly. 
Spheroids/well were counted using a Leica DMD108 
digital microimaging instrument (Leica Microsystems, 
Milan, Italy) and the spheroids diameter was calculated 
using AxioVision software rel. 4.8 (Oberkochen, 
Germany).
Nucleic acids isolation and genetic 
characterization of matched tissues  
and thyroid spheroids
All tissues and thyroid spheroids were submitted to 
genetic characterization. According to data available in the 
literature related to the most common mutational pattern of 
different thyroid cancer histotypes, we screened PTCs for 
RET and TRK common rearrangements, TERT, BRAF and 
RAS common point mutations, and FTCs only for TERT 
and RAS mutations [33-36]. The analysis of TRK and/or 
RAS was not done in 5 (#1, 5, 8, 19, 30) papillary tumors, 
due to the lack of high quality material. Nucleic acids were 
extracted from tissues samples, by means of a commercial 
kit (Puregene® Core kit A, Qiagen Sciences, Maryland, 
USA) and from thyroid spheroids using the AllPrep 
DNA/RNA Micro Kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s specifications. DNAs 
were then used for the screening of known point mutations 
in the BRAF, H-, N-, K-RAS, TERT genes, while RNAs 
were retro-transcribed and amplified with appropriate 
primers for the identification of TRK and TRK-T1/T2/T3 
and RET-PTC1/PTC2/PTC3 rearrangements, as previously 
described [33, 37-41]. Primers and PCR conditions used 
are reported in the Supplementary Table 1.
Immunostaining of thyroid spheroids and tissues
Thyroid spheroids were harvested after 7 days, 
centrifuged at 300g for 5 minutes and the pellet was 
included in 1% Agar in PBS, fixed in formalin and 
paraffin-embedded. Consecutive paraffin sections of 3 µm 
were cut and used for immunohistochemistry analyses. 
The first slide was stained with hematoxylin/eosin for 
morphological examination of the spheroids. Subsequent 
slides were submitted to immunostaining with antibodies 
against markers of stem cells (POU5F1/OCT4, Santa 
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Cruz Biotechnology Inc., Dallas, TX, USA; NANOG, 
ReproCELL Inc., Yokohama, Kanagawa, Japan), thyroid 
progenitors (TTF1, Cell Marque, Rocklin, CA, USA), 
mature thyroid cells (TG, Cell Marque, Rocklin, CA, 
USA), endothelial cells (CD31, Cell Marque, Rocklin, 
CA, USA), hematopoietic progenitor/stem cells (CD34, 
Cell Marque, Rocklin, CA, USA), leucocytes (CD45, 
Cell Marque, Rocklin, CA, USA). Clones, commercial 
brands, dilutions and length of incubation/temperature of 
the antibodies used are reported in Supplementary Table 
2. Appropriate secondary antibodies and detection systems 
were used in an automatic immunostainer (Bench Mark 
Ultra, Ventana Medical Systems Inc., Tucson, USA). 
Staining was revealed using the UltraView Universal 
DAB (Ventana Medical Systems Inc., Tucson, USA) and 
counterstained with hematoxylin. Paraffin sections of 
appropriate tissues (tonsil for CD31, CD34 and CD45; 
thyroid for thyroglobulin; lung adenocarcinoma for TTF1; 
seminoma for POU5F1/OCT4 and NANOG) were used as 
positive controls. Primary antibody omission was used as 
negative control. For quantification of immunoreactivity, 
four high-power fields per tissue and at least 10 spheroids 
per case were viewed by two independent pathologists (SB 
and SF). Representative images of all stainings were then 
obtained using a Leica DMD108 digital microimaging 
instrument (Leica Microsystems, Milan, Italy). For CD31, 
CD34 and CD45 positive cells were scored out of the total 
number on cells within at least 5 spheres for each sample 
and expressed as a percentage. The staining intensity was 
not considered due to homogeneous expression of the 
markers among samples.
SP600125 (SP) treatment
SP anti-proliferative effects were assessed on 
thyroid multicellular spheroids derived from 6 PTCs, 
1 FTC and their corresponding normal spheroids. 
Tumor and normal thyroid spheroids were obtained, as 
described above, plating cells at a density of 105 cells 
per well in ultra-low attachment 24-well plates (Corning 
Incorporated Life Science, Tewksbury, MA, USA). 
SP600125 (Sigma-Aldrich, Saint Louis, MO, USA) was 
dissolved in DMSO (Sigma-Aldrich, Saint Louis, MO, 
USA) to yield a stock solution of 20 mM, which was 
stored at −20 °C. SP concentration to be used (20 μM) 
and the duration of treatment (96 hours), were chosen 
based on our previous data on monolayer cultures [8] and 
on preliminary experiments (not shown). Non-treated 
thyroid spheroids were also used as control. The plates 
were then placed in a 37 °C, 5 % CO2 incubator. After 
4 days of treatment, cells were harvested for proteins 
extraction. Spheroids/well were manually counted using 
a Leica DMD108 digital microimaging instrument (Leica 
Microsystems, Milan, Italy) and the scale bars were 
applied using AxioVision software rel. 4.8 (Oberkochen, 
Germany).
Protein extraction and proliferation assay
Briefly, the pellet of the spheroids obtained from 
6 PTCs, 1 FTC and from their corresponding normal 
thyroid tissues were grown for 2 weeks and harvested 
for non-treated, DMSO treated (DMSO, 20 μM) and SP 
treated (SP, 20 μM) evaluation after additional 96 hours. 
They were homogenized and lysed in a constant amount 
of RIPA buffer (10 mM Tris-HCl pH 7.5, 500 mM NaCl, 
0.1% SDS, 1% NP40, 1% Na-deoxycholate, 2 mM 
EDTA), supplemented with complete protease inhibitors 
cocktail tablets (Roche, Basel, Switzerland). After 
sonication, 5μL of protein extracts were used for protein 
determination with Pierce BCA protein assay kit (Thermo 
Fisher, Waltham, Massachusetts, USA). Each sample was 
measured in duplicate and samples immediately stored at 
-80°C.
Western blot analysis
Thirty micrograms of protein extracts were 
separated on NuPAGE Novex 4-12% Bis-Tris Protein 
Gels (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) and electrotransferred to nitrocellulose membranes 
with iBlot System (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). The quality and uniformity of 
protein transfer was checked through Ponceau S solution 
staining (Sigma-Aldrich, Saint Louis, MO, USA). 
Membranes were blocked with 5% milk TBS-T, probed 
overnight at 4°C with β-catenin primary antibody and 
incubated with the appropriate HRP-conjugated secondary 
antibody for 1 h at room temperature. GAPDH (Ambion-
Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) was used as housekeeping control. In preliminary 
experiments, samples were blotted with different proteins 
(actin, α-tubulin and GAPDH) usually used as loading 
control, and GAPDH was found to be the most reliable. 
The results obtained with GAPDH were comparable to 
those obtained with Ponceau S staining, which is often 
used as an alternative method to evaluate the total protein 
amount [42]. The detection was performed using the 
Luminata Forte Western HRP substrate (Merck Millipore, 
Vimodrone, Italy). Bands of interest were quantified 
using ImageJ software version 1.47 (National Institute of 
Health, Bethesda, MD). In order to reduce interindividual 
variability, tissue extracts were used as reference control. 
Each sample set (normal or tumor tissue derived) was 
then normalized accordingly. Clones, commercial brands, 
dilutions and length of incubation/temperature of all the 
antibodies used are reported in Supplementary Table 2.
ROCK activity assay
ROCK activity was measured with Rho-associated 
Kinase (ROCK) Activity Assay (Millipore, Billerica, MA, 
USA). Five micrograms of protein extracts were loaded 
per well and enzyme activity was subsequently determined 
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following the manufacturer’s instructions. Each sample 
was measured in duplicate. Colorimetric reaction was 
detected at 450nm using ELx800 Absorbance Microplate 
Reader (BioTek, Winooski, VT, USA).
Statistical analysis
Statistical analyses were performed with GraphPad 
Prism Software, Inc., version 5.04 (La Jolla, CA USA). 
The normality of samples distribution was checked with 
Kolmogorov-Smirnov test. Given that some of the samples 
resulted not normally distributed within each group, and 
also considering the low number of patients tested with SP 
treatment, the normality assumptions were considered as 
violated. We thus checked if our data sets were statistically 
different from each other with non-parametric Mann-Whitney 
test for direct comparison of two sample sets, and with non-
parametric ANOVA on ranks when more than two sample sets 
were compared. Differences among the sizes and the number 
of spheroids derived from different tissues and among the 
percentages of staining for endothelial and hematopoietic 
markers were evaluated by t-test. All experiments were 
performed at least four times in duplicate. The difference 
between values was considered significant when P<0.05.
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